Immune Checkpoint Inhibitors Nephrotoxicity

Launched by R. LAURA VICENTE VICENTE · May 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the potential kidney damage caused by a type of cancer treatment called immune checkpoint inhibitors (ICIs). While ICIs can be very effective in fighting cancer, they can also lead to side effects, including kidney injury. The researchers believe that some kidney damage might not show up in standard lab tests, so they want to look for new markers in urine that could help identify and manage kidney issues early on. By understanding these markers, doctors can better care for patients receiving ICIs, improving their overall health and quality of life.

To participate in this trial, individuals should be between 18 and 75 years old and are waiting to start immunotherapy or a combination of immunotherapy with platinum-based drugs. However, patients who are terminally ill or do not want to sign consent forms will not be included. Those who join the study can expect to provide urine samples and undergo tests that will help scientists learn more about kidney function during cancer treatment. This research aims to enhance how doctors monitor and treat patients receiving ICIs, ultimately leading to better outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients waiting for immunotherapy or combination immunotherapy / platinum compounds
• Exclusion Criteria:
• • Patients who are terminally ill
• • Patients who do not wish to sign the informed consent